Dunedin-based Blis Technologies has booked a $780,000 loss
for the six months to September, reiterating earlier guidance
it still faces a full-year loss of $1.3 million.
In its third capital-raising since listing in 2004, Blis
raised $1.31 million in a shareholder purchase plan and
private placement over September-October, having delivered
eight consecutive losses totalling almost $8 million. Revenue
for the half was $580,000.
Blis, which develops oral probiotoc bacteria, spent $226,000
during the half year on capitalising development costs and
patent costs, and spent $225,000 last year acquiring city
company Gourmet Ice Cream.
The $1.3 million capital raised is earmarked for launching
Blis K12 ice cream, Blis M18 dietary supplements and
international product sales.
In a statement yesterday, Blis also reiterated that unless
additional funding could be found, a capital raising through
a pro-rata issue to shareholders was "likely", alongside a
review of operations during 2014.
Blis exports to Australia, Asia and Europe. A China launch
was deferred and some distribution in the United States